Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 379 results for lung cancer

  1. Managed access

    Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

  2. What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non‑small‑cell lung cancer following multimodality treatment including surgery?

    effectiveness of immunotherapy in people with stage IIIA-N2 non‑small‑cell lung cancer following multimodality treatment including...

  3. Artificial intelligence for analysing chest CT images (MIB243)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .

  4. Cardiovascular disease: identifying and supporting people most at risk of dying early (PH15)

    This guideline covers the risk of early death from heart disease and other smoking-related illnesses. It aims to reduce the number of people who are disadvantaged dying prematurely by ensuring people have better access to flexible, well-coordinated treatment and support.

  5. ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment (MIB39)

    NICE has developed a medtech innovation briefing (MIB) on ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment

  6. Sigvotatug vedotin for Non-small-cell lung cancer [ID6718]

    Awaiting development Reference number: GID-TA11942 Expected publication date: TBC

  7. NICE visualisation of treatment options incorporating technology appraisals: interim process guide (PMG38)

    This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input

  8. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

    Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.

  9. What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell lung cancer following multimodality treatment including surgery?

    effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell lung cancer following multimodality treatment including...

  10. Photodynamic therapy for advanced bronchial carcinoma (HTG54)

    Evidence-based recommendations on photodynamic therapy for advanced bronchial carcinoma. This involves giving the patient something that makes them sensitive to light, then using special equipment to shine light onto the cancer to activate the substance and destroy some of the cancer.

  11. What is the cost effectiveness and safety of non-surgical ablation and stereotactic body radiotherapy compared to resection for people with metastatic colorectal cancer in the lung amenable to local treatment?

    radiotherapy compared to resection for people with metastatic colorectal cancer in the lung amenable to local treatment?...

  12. More research is needed on the following artificial intelligence (AI)‑derived software to analyse chest X‑rays alongside clinician review for suspected lung cancer in adults referred from primary care:

    software to analyse chest X‑rays alongside clinician review for suspected lung cancer in adults referred from primary care: Any...

  13. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  14. VIDAvision for lung volume analysis in emphysema (MIB148)

    NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .